Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

PHASE2RecruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions

ER+/HER2- Breast Cancer

Interventions

PROCEDURE

HIFU

HIFU therapy is administered to the targeted breast lesion site.

DRUG

Toripalimab

240 mg, IV infusion, Q3W

DRUG

nab-Paclitaxel (nab-P)

125 mg/m2, IV infusion, QW

DRUG

Epirubicin (E)

90 mg/m2, IV infusion, Q3W

DRUG

Cyclophosphamide (C)

600 mg/m2, IV infusion, Q3W

Trial Locations (1)

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER